Compugen Announces Interim Analysis Timeline for MAIA-Ovarian Trial of COM701 as Maintenance Therapy in Platinum-Sensitive Ovarian Cancer

Reuters
2025.10.13 11:01
portai
I'm PortAI, I can summarize articles.

Compugen Ltd. has announced an interim analysis timeline for its MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in platinum-sensitive ovarian cancer. The analysis will occur after data from about 60 participants is collected, with results expected by the end of 2026. Clinical sites have been activated in the U.S., Israel, and France to support enrollment. Additionally, a pooled analysis of COM701 from three Phase 1 trials will be presented at ESMO 2025, with the abstract available on the company’s website and the poster set for release on October 18, 2025.

Compugen Ltd. has announced new developments regarding its clinical programs in ovarian cancer. The company is currently conducting the MAIA-ovarian trial, evaluating COM701 as a maintenance therapy in relapsed platinum-sensitive ovarian cancer. An interim analysis is planned once data from approximately 60 participants are available, with results estimated by year end 2026. To support enrollment, Compugen has activated clinical sites in the U.S., Israel, and France. Additionally, Compugen will present a pooled analysis of COM701 in three Phase 1 trials involving patients with platinum-resistant ovarian cancer at ESMO 2025. The abstract for this analysis is already available on the company’s website, and the poster will be released on October 18, 2025. The pooled analysis provides support for the ongoing MAIA-ovarian trial of COM701. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO96101) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.